CD19-CAR T在难治复发急性B淋巴细胞白血病中应用

Application of CD19-CAR T Cells in Refractory Relapsed Acute B Lymphocyte Leukemia

目的:探讨CD19-CAR T(chimeric antigen receptor-modified T)细胞在难治复发急性B淋巴细胞白血病的疗效。方法:回顾性分析2015年1月至2017年7月在北京大学第三医院血液科采用CD19-CAR T细胞治疗的难治复发的急性B淋巴细胞白血病(B-ALL,B-acute lymphoblastic leukemia)患者的疗效和副作用。结果:共有10例患者被纳入本分析,均符合难治复发急性B淋巴细胞白血病的诊断,白血病细胞免疫分型均为CD19+。接受CD19-CAR T细胞治疗后28 d的总反应率(overall response rate,ORR)为70%(7/10),其中6例完全缓解(complete remission,CR)(60%),1例部分缓解(partial remission,PR)(10%); 90 d CR率为30%。结论:CD19-CAR T细胞治疗难治复发急性B淋巴细胞白血病有效,不良反应可控。

Objective: To investigate the efficacy of CD19 - targeted chimeric antigen receptor T-cell ( CD19 - CAR T) in the treatment of patients with refractory relapsed B cell acute lymphocyte leukemia( B-ALL) .Methods: The efficacy and safety of CD19 - CAR T cells in treatment of patients with refractory relapsed B-ALL from January 2015 to July 2017 in the Department of Hematology of Peking University Third Hospital were analyzed retrospectively.Results: A total of 10 patients were included in this analysis,all of which were consistent with the diagnosis of refractory relapsed B-ALL,and the immunophenotype of leukemia cells was CD19 positive.After treatment with CD19 - CAR T cells,the overall response rate( ORR) on day 28 was 70%.Among them,6 cases reached complete remission ( CR) ,1 case reached partial remission( PR) .The rate of CR on day 90 was 30%.Conclusion: CD19 - CAR T cells are effective in the treatment of refractory relapsed B-ALL,and the adverse reactions are controllable.